MedTrace Logo

Probenecid Administration for Alcohol Craving and Consumption

NCT07118618 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-03-17

No results posted yet for this study

Summary

This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.

Conditions

  • Alcohol Use Disorder (AUD)
  • Alcohol Consumption
  • Craving

Interventions

DRUG

Probenecid Oral Tablet

2gr daily

DRUG

Placebo Oral Tablet

Inactive compound

Sponsors & Collaborators

  • Brown University

    lead OTHER

Principal Investigators

  • Carolina Haass-Koffler, PharmD, PhD · Brown Univiversity

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-14
Primary Completion
2030-12-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07118618 on ClinicalTrials.gov